Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly & Co.

www.lilly.com

Latest From Eli Lilly & Co.

Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US

US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.

Approvals Metabolic Disorders

What’s At Stake As China Expands '4+7' Scheme: An Infographic Snapshot

China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.

China Policy & Regulation

ESMO Preview: Five Key Oncology Battlegrounds To Watch

GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.

Cancer Research & Development

Bucking Biosimilar Threat, Roche Sees Further Growth

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

Cancer Neurology
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register